LEXX

Lexaria Bioscience Corp. LEXX

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,876 of 2,925

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to May 31

Net income

$-1.99M

Quarter to May 31

Free cash flow

$-1.64M

Quarter to May 31

Top Institutional Holders

as of Q2 2026
$920.0K total
Reading the latest SEC filing…

Key Metrics

Revenue

Q3 2026
EDGAR

Net Income

Q3 2026
EDGAR

EPS (Diluted)

Q3 2026
EDGAR

Free Cash Flow

Q3 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/LEXX

Earnings Per Share

13fpro.ai/company/LEXX

Loading ratio trend…

LEXX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Lexaria Bioscience Corp. (LEXX): stock profile, AI score and financials

Lexaria Bioscience Corp. (LEXX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LEXX at 9.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,876 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q3 2026), Lexaria Bioscience Corp. reports net income of $-2.0M, free cash flow of $-1.6M. LEXX trades on the Nasdaq exchange and files with the SEC under CIK 1348362. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LEXX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lexaria Bioscience Corp. directly from SEC EDGAR.

SEC EDGAR: CIK 1348362 →